Article

Prospective evaluation of pretreatment executive cognitive impairment and depression in patients referred for radiotherapy

Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
International Journal of Radiation OncologyBiologyPhysics (Impact Factor: 4.18). 05/2008; 72(2):529-33. DOI: 10.1016/j.ijrobp.2007.12.040
Source: PubMed

ABSTRACT Cancer patients are at risk of cognitive impairment and depression. We sought to ascertain the prevalence of executive, visuospatial, memory, and general cognitive performance deficits before radiotherapy in a radiation oncology clinic referral population and correlate the neurocognitive measures with the depression symptom burden.
A total of 122 sequential patients referred for radiotherapy evaluation were administered a test battery composed of the Executive Interview (EXIT25), Executive Clock Drawing Task (CLOX1 and CLOX2), Mini Mental State Examination (MMSE), Memory Impairment Screen (MIS), and Geriatric Depression Scale (GDS). The mean age +/- standard deviation was 58 +/- 17 years. Of 122 patients, 24 (20%) had been referred for breast cancer, 21 (17%) for gastrointestinal cancer, 17 (14%) for genitourinary disease, and 8 (7%) for brain lesions; the rest were a variety of tumor sites. The cognitive performance among the tumor cohorts was compared using Bonferroni-corrected analysis of variance and Tukey-Kramer tests. Pearson correlation coefficients were determined between each cognitive instrument and the GDS.
Of the 122 patients, 52 (43%) exhibited a detectable executive cognition decrement on one or more test measures. Five percent had poor memory performance (MIS), 18% had poor visuospatial performance (CLOX2), and 13% had poor global cognition (MMSE). Patients with brain tumors performed substantially worse on the EXIT25. No between-group differences were found for CLOX1, CLOX2, MIS, or GDS performance. The EXIT25 scores correlated significantly with the GDS scores (r = 0.26, p = 0.005).
The results of this study have shown that patients referred for radiotherapy exhibit cognitive impairment profiles comparable to those observed in acutely ill medical inpatients. Executive control impairment appears more prevalent than global cognitive deficits, visuospatial impairment, or depression.

0 Followers
 · 
76 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nitroxyl contrast agents (nitroxyl radicals, also known as nitroxide) are paramagnetic species, which can react with reactive oxygen species (ROS) to lose paramagnetism to be diamagnetic species. The paramagnetic nitroxyl radical forms can be detected by using electron paramagnetic resonance imaging (EPRI), Overhauser MRI (OMRI), or MRI. The time course of in vivo image intensity induced by paramagnetic redox-sensitive contrast agent can give tissue redox information, which is the so-called redox imaging technique. The redox imaging technique employing a blood-brain barrier permeable nitroxyl contrast agent can be applied to analyze the pathophysiological functions in the brain. A brief theory of redox imaging techniques is described, and applications of redox imaging techniques to brain are introduced.
    Methods in molecular biology (Clifton, N.J.) 01/2011; 711:397-419. DOI:10.1007/978-1-61737-992-5_20 · 1.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer creates an important psychological suffering that reaches clinical levels of distress in half of those who suffer from it. Cancer is accompanied by psychopathological disorders in more than 30 % of the cases, a prevalence higher than in the general population which requires specialised psychological attention. The emotional distress is high from the beginning to the end of the medical treatment and it is a risk factor for psychopathological disorders. These problems require adequate screening and assessment, often hampered by various reasons. Simple tools are needed, easy to use in medical consultations and appropriate to detect emotional distress and mental health problems that these people may suffer, thus facilitating the referral of these patients to the psycho-oncologist in order to provide the specific treatment to those who need it in the context of comprehensive care for cancer patients. This objective involves all health professionals.
    Clínica y Salud 01/2013; 24(1):1–9. DOI:10.5093/cl2013a1
  • [Show abstract] [Hide abstract]
    ABSTRACT: Most patients with localized breast cancer (LBC) who take adjuvant chemotherapy (CT) complain of fatigue and a decrease in quality of life during or after radiotherapy (RT). The aim of this longitudinal study was to compare the impact of RT alone with that occurring after previous CT on quality of life. Fatigue (the main endpoint) and cognitive impairment were assessed in 161 CT-RT and 141 RT patients during RT and 1 year later. Fatigue was assessed with Functional Assessment of Cancer Therapy-General questionnaires, including breast and fatigue modules. At baseline, 60% of the CT-RT patients expressed fatigue vs. 33% of the RT patients (p <0.001). Corresponding values at the end of RT were statistically similar (61% and 53%), and fatigue was still reported at 1 year by more than 40% of patients in both groups. Risk factors for long-term fatigue included depression (odds ratio [OR] = 6), which was less frequent in the RT group at baseline (16% vs. 28 %, respectively, p = 0.01) but reached a similar value at the end of RT (25% in both groups). Initial mild cognitive impairments were reported by RT (34 %) patients and CT-RT (24 %) patients and were persistent at 1 year for half of them. No biological disorders were associated with fatigue or cognitive impairment. Fatigue was the main symptom in LBC patients treated with RT, whether they received CT previously or not. The correlation of persistent fatigue with initial depressive status favors administering medical and psychological programs for LBC patients treated with CT and/or RT, to identify and manage this main quality-of-life-related symptom.
    International journal of radiation oncology, biology, physics 09/2010; 81(3):795-803. DOI:10.1016/j.ijrobp.2010.06.037 · 4.18 Impact Factor

Full-text (2 Sources)

Download
24 Downloads
Available from
May 17, 2014